PSMA Targeted Indium-111 Labeled Trillium Compound - Ratio Therapeutics
Alternative Names: In-111 labelled trillium compoundsLatest Information Update: 02 Jul 2024
At a glance
- Originator Ratio Therapeutics
- Class Antineoplastics; Drug conjugates; Radioisotopes; Radiopharmaceuticals; Small molecules
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase 0 Prostate cancer
Most Recent Events
- 05 Apr 2024 Pharmacodynamics data from the preclinical studies in Prostate cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 12 Dec 2023 Ratio Therapeutics completes a phase 0 trial in Prostate cancer (Metastatic disease) in USA (unspecified route) (NCT05773703)
- 08 Dec 2022 Phase-0 for Prostate cancer (Metastatic disease) in USA (unspecified route) (NCT05773703)